يعرض 1,661 - 1,680 نتائج من 13,319 نتيجة بحث عن '(( significant increase decrease ) OR ( significant ((inter decrease) OR (greater decrease)) ))', وقت الاستعلام: 0.29s تنقيح النتائج
  1. 1661

    Initial participants by wave*. حسب Yeo Ju Sohn (18536198)

    منشور في 2024
    الموضوعات:
  2. 1662
  3. 1663
  4. 1664
  5. 1665
  6. 1666
  7. 1667
  8. 1668
  9. 1669

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  10. 1670

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  11. 1671

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  12. 1672
  13. 1673
  14. 1674
  15. 1675
  16. 1676
  17. 1677
  18. 1678
  19. 1679
  20. 1680